Witryna6 kwi 2015 · A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] - Full Text View - ClinicalTrials.gov Home Search Results Study Record Detail Save this study Witryna• Performed routine cell culture lab work including vial thaw, cell freeze, and mammalian cell culture maintenance • Executed a myriad of timeline-oriented cell line development strategies ...
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Witryna23 mar 2024 · An update from the phase 3 IMpower010 study shows that the study has met its primary end point of improvement in disease-free survival with atezolizumab versus use of best supportive care as treatment of … Witryna10 kwi 2024 · Small cell lung cancer is a highly proliferative, aggressive form of lung cancer that carries a poor prognosis for close to 40 years, and the preferred decades old treatment is platinum etoposide. ... But more importantly, especially after the results from the IMpower 133 trial, we now know that the small cell lung cancer can be stratified ... hidrautecno
A Win for Small-Cell Lung Cancer: IMPOWER 133 - OncLive
Witryna18 maj 2024 · Efficacy was evaluated in IMpower110 (NCT02409342), a multicenter, international, randomized, open-label trial in patients with stage IV NSCLC whose tumors express PD-L1 (TC ≥ 1% or IC ≥ 1%), who... Witryna20 wrz 2024 · IMpower010 is a randomised, multicentre, open-label, phase 3 study of atezolizumab versus best supportive care after adjuvant cisplatin-based … Witryna31 mar 2024 · As presented at the European Lung Cancer Congress (ELCC) 2024 (Copenhagen, 29 March–1 April), updated data from the EMPOWER-Lung 1 (Lancet. 2024;397:592–604) and EMPOWER-Lung 3 (Nat Med. 2024;28:2374–2380) trials confirm a durable activity of the immunotherapeutic, cemiplimab, in non-small cell … hid readfile